We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Innovative Platform to Address Need for Fast and Accurate POC Testing for Infectious Diseases

By LabMedica International staff writers
Posted on 22 Sep 2023
Print article
Image: The MiCRIA Open POC platform uses reagents that can be made anywhere, by anyone in a basic, standard laboratory (Photo courtesy of Kephera Diagnostics)
Image: The MiCRIA Open POC platform uses reagents that can be made anywhere, by anyone in a basic, standard laboratory (Photo courtesy of Kephera Diagnostics)

Emerging infectious diseases account for over a billion cases of illness each year and are a major cause of death globally. Vector-borne diseases like mosquitoes are especially dangerous, putting over half of the world's population at risk, as per the World Health Organization. Accurate diagnosis is critical for the effective management of infectious diseases, but traditional lab tests often come with drawbacks like high costs, complexity, slow development, and limited global availability. To tackle these issues, a new open point-of-care (POC) platform aims to provide quick and accurate POC testing for emerging and neglected infectious diseases.

Kephera Diagnostics’ (Framingham, MA, USA) MiCRIA Open POC platform aims to fulfill the need for rapid POC testing on a global scale. The platform uses easily produced reagents, allowing for universal accessibility of precise, two-minute POC tests, even in areas lacking resources. Unlike other tests that require disease-specific strips or cartridges, this patent-pending system employs a generic cassette and assay-specific reagents. Furthermore, the assay is based on microfluidic technology rather than membrane-based methods.

The test-specific reagent is derived by an antibody, antigen, or other ligand, and can be quickly mass-produced using standard laboratory equipment. The platform features a compact and economical reader that can be managed through a smartphone or another mobile device to conduct tests as well as interpret and display results. Kephera's MiCRIA Open POC platform has shown to have better sensitivity compared to lateral flow rapid tests and is almost as effective as ELISA tests.

Related Links:
Kephera Diagnostics 

Gold Member
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Automated Blood Typing System
IH-500 NEXT
New
LH ELISA
Luteinizing Hormone ELISA
New
Leishmania Test
Leishmania Real Time PCR Kit

Print article

Channels

Clinical Chemistry

view channel
Image: The new saliva-based test for heart failure measures two biomarkers in about 15 minutes (Photo courtesy of Trey Pittman)

POC Saliva Testing Device Predicts Heart Failure in 15 Minutes

Heart failure is a serious condition where the heart muscle is unable to pump sufficient oxygen-rich blood throughout the body. It ranks as a major cause of death globally and is particularly fatal for... Read more

Hematology

view channel
Image: The smartphone technology measures blood hemoglobin levels from a digital photo of the inner eyelid (Photo courtesy of Purdue University)

First-Of-Its-Kind Smartphone Technology Noninvasively Measures Blood Hemoglobin Levels at POC

Blood hemoglobin tests are among the most frequently conducted blood tests, as hemoglobin levels can provide vital insights into various health conditions. However, traditional tests are often underutilized... Read more

Immunology

view channel
Image: Under a microscope, DNA repair is visible as bright green spots (“foci”) in the blue-stained cell DNA. Orange highlights actively growing cancer cells (Photo courtesy of WEHI)

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Every year, hundreds of thousands of women across the world are diagnosed with ovarian and breast cancer. PARP inhibitors (PARPi) therapy has been a major advancement in treating these cancers, particularly... Read more

Microbiology

view channel
Image: HNL Dimer can be a novel and potentially useful clinical tool in antibiotic stewardship in sepsis (Photo courtesy of Shutterstock)

Unique Blood Biomarker Shown to Effectively Monitor Sepsis Treatment

Sepsis remains a growing problem across the world, linked to high rates of mortality and morbidity. Timely and accurate diagnosis, along with effective supportive therapy, is essential in reducing sepsis-related... Read more

Pathology

view channel
Image: The artificial intelligence models can personalize immune therapies in oncology patients (Photo courtesy of 123RF)

AI Tool Identifies Novel Genetic Signatures to Personalize Cancer Therapies

Lung cancer and bladder cancer are among the most commonly diagnosed cancers globally. Researchers have now developed artificial intelligence (AI) models designed to personalize immune therapies for oncology... Read more

Technology

view channel
Image: Schematic diagram of nanomaterial-based anti-epileptic drug concentration diagnostic technology (Photo courtesy of KRISS)

Nanomaterial-Based Diagnostic Technology Accurately Monitors Drug Therapy in Epilepsy Patients

Many patients with epilepsy take anti-epileptic drugs to control frequent seizures in their daily lives. To optimize treatment and avoid side effects from overdosing, it is crucial for patients to regularly... Read more
Copyright © 2000-2024 Globetech Media. All rights reserved.